Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 1,301–1,400 of 2,039
Michelet, A., Mowla, M., Amo-Brown, B. A., Rodriguez, N., & Cavaretta, M. J. (2025) · Hospital Pharmacy · doi:10.1177/00185787251372054 · Cited by 4
“21 Tirzepatide also has a terminal half-life of 5 days and semaglutide’s is 7 days.”
Advent of tirzepatide: boon for diabetic and obese?
Bhusal, A. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000173 · Cited by 2
Effet du bi-agoniste GLP-1/GIP sur le poids, le tissu adipeux et les lipides
Vergès, B. L. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.06.004 · Cited by 3
Gelhorn, H. L., Maher, S. M., Sapin, H., Poon, J. L., & Boye, K. S. (2023) · Quality of Life Research · doi:10.1007/s11136-023-03476-0 · Cited by 2
“The primary objective of this work was to derive an MIC for improvement in the IW-SP total score among individuals with T2D using data from the SURPASS-2 trial [9].”
MethodMetabolism and Target Organ Damage
Fearon, N. M., & Pournaras, D. J. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.12 · Cited by 3
Suboptimal Weight Loss After Bariatric Surgery: Mechanisms and Treatment Algorithms
Mok, J., & Batterham, R. L. (2023) · Springer eBooks · doi:10.1007/978-3-030-60596-4_118 · Cited by 2
A „másik” inkretin – a glükózdependens insulinotrop polipeptid terápiás újrafelfedezése
Winkler, G., Kis, J. T., & Schandl, L. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32710 · Cited by 5
Yang, J. N., Yang, Q., Fang, Y., & Liu, F. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s400225 · Cited by 2
Obesity-related hypertension: Implications for advanced nursing practice
Benenson, I., & Prado, K. (2023) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000055 · Cited by 2
Khan, Z., Naeem, M. O., Khan, S. K., Khan, F., Abdullah, M., Attique, I., Muhammad, S. D., & Amin, A. (2023) · Cureus · doi:10.7759/cureus.44314 · Cited by 3
“Frias et al [15] 2021 Add-on therapy 5 mg 470 40 Weeks 56.”
Müller‐Wieland, D., Brandts, J., Verket, M., Marx, N., & Schütt, K. S. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_537 · Cited by 4
Diabetic retinopathy screening and treatment
Nissen, T. P. H. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau588589522 · Cited by 2
GLP-1 Receptor Agonists vs Alternatives for Alcohol Use Disorder: A Multi-Target Trial EmulationPreprint
Rodriguez, P. J., Lusk, J. B., Mehta, H. B., Levy, J. F., Kalogeropoulos, A. P., Soneji, S. S., Webber, E., Gluckman, T. J., & Stucky, N. L. (2025) · medRxiv · doi:10.1101/2025.06.07.25329184 · Cited by 2
Tratamiento farmacológico del paciente que vive con diabetes mellitus tipo 2
Rincón, A. R., Betancur, S. S., Ramos, A. F. G., González-Arango, J., & Vargas, L. V. E. (2022) · CES Medicina · doi:10.21615/cesmedicina.6672 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Les médicaments de l’obésité : état actuel et futures avancées
Lassen, P. B., & Aron‐Wisnewsky, J. (2023) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2023.04.005 · Cited by 3
Kim, S. Q., Kim, J., Choi, M. R., Kim, J., Kim, S., & Kim, Y. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149164 · Cited by 1
Goldenberg, R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15381 · Cited by 1
Evolution of Management of Diabetes Mellitus
Uddin, K. N. (2024) · Bangladesh Journal of Medicine · doi:10.3329/bjm.v35i1.70738 · Cited by 1
Glucagon and the metabolic syndrome
Welch, A., & Vella, A. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00011-6 · Cited by 2
SEMAGLUTIDE (OZEMPIC) A POTENT WEAPON IN THE FIGHT AGAINST OBESITY
Mukhtar, B. B. (2024) · Pakistan Postgraduate Medical Journal · doi:10.51642/ppmj.v35i01.694 · Cited by 1
Vázquez, L. A., Tofé, S., Bellido, D., Botella-Serrano, M., Soto-González, A., Mezquita‐Raya, P., Delgado, E., Fajardo, C., Morales, C., Causanilles, A., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01587-6 · Cited by 2
“The incidence of these GI effects was similar to that reported with semaglutide 1 mg [5].”
MethodResultBao, Y., Han, L., Du, L., & Ji, L. (2024) · Obesity · doi:10.1002/oby.24030 · Cited by 1
Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes
Strollo, F., Guarino, G., Satta, E., & Gentile, S. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01624-4 · Cited by 1
“They were primarily mild to moderate in severity in the tirzepatide and semaglutide groups, with nausea occurring in 1.3%, 1.5%, and 0.9% vs. 0.9%, respectively; vomiting in 0.2%, 0.9%, and 0.9% vs. 0.6%, respectively; diarrhea in 0.2%, 0.6%, and 1.3% vs. 0.6%, respectively [4].”
BackgroundInfluentialGLP-1 and GIP analogues in the treatment of obesity
Jasińska-Balwierz, A., Balwierz, R. J., Biernat, P., Makieieva, N., Tomków, M., Cesarz, K., Osowski, M., Dorożyński, B., Skotnicka-Graca, U., & Lipok, J. (2024) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2024.0023 · Cited by 2
Ibrahim, E., Burken, M., Lastra, G., & Manrique‐Acevedo, C. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00765.2024 · Cited by 3
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes · doi:10.2337/dbi24-0046 · Cited by 1
Winberg, D., Nauman, E., Shi, L., Mohundro, B. L., Louis, K., Price‐Haywood, E. G., Tang, T., & Bazzano, A. N. (2025) · Health Research Policy and Systems · doi:10.1186/s12961-024-01278-5 · Cited by 1
“…required enrolment and/or engagement in the health plan’s disease management, Blue Cross expanded the program in 2020 to include all fully insured members with an eligible benefit plan, regardless of whether they participate in disease management (the current version is referred to as 3.0) [14].”
InfluentialKidney Transplant and Cardiovascular-Kidney-Metabolic Health
Jittirat, A., Levea, S.-L. L., Concepcion, B. P., & Shawar, S. H. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.004 · Cited by 4
Hayman, M. M. E., Jones, W., Aman, A., Ward, J., Anderson, J. J., Lyall, D. M., Pell, J. P., Sattar, N. A., Welsh, P. I., & Strawbridge, R. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16178 · Cited by 3
Piťhová, P. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.009 · Cited by 1
Zhang, J., Wang, C., Wang, J., Gu, W., Wang, H., Zhu, H., Ma, X., & Shi, Z. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-05664-9 · Cited by 1
“Semaglutide, as one of the GLP-1RAs, is an effective and FDA-approved treatment option for weight control mainly by suppressing appetite [13–15].”
Person Centered Approach and Challenges in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_7 · Cited by 4
FDG PET/CT Images Demonstrating Subclinical Pancreatitis in a Patient on a GLP-1 Receptor Agonist
Lenkov, R., Berman, T., Mehmi, I., et al. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005856 · Cited by 1
Grenet, G., Gougeon, A., Salzwedel, D. M., Jauca, C. D., & Wright, J. M. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016144 · Cited by 3
Obesity and Hypertension: Etiology and the Effects of Diet, Bariatric Surgery, and Antiobesity Drugs
Elattar, S., Chand, S., Salem, A. M., Abdulfattah, A., Bassiony, M. A. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000937 · Cited by 2
Dosing Exercise to Regulate Cardiometabolic Risk Among People Requiring Cardiac Rehabilitation
Gordon, B. A., Parr, E. B., & Schultz, M. G. (2025) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000361 · Cited by 1
Alicic, R. Z., & Neumiller, J. J. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.003 · Cited by 1
Setting Expectations When Prescribing Medication for the Treatment of Patients With Obesity
Fitch, A. (2025) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2025.100621 · Cited by 3
Brož, J. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.026 · Cited by 1
Ordemann, J., & Elbelt, U. (2025) · Herz · doi:10.1007/s00059-025-05319-9 · Cited by 1
Biased Agonism in Incretin-based Therapies
Seshadri, K. (2025) · International journal of clinical metabolism and diabetes. · doi:10.1177/30502071251336542 · Cited by 1
“14 In this study, the A1C reduction with the lowest dose of TZP was greater than semaglutide.”
Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus
Xu, C.-L., Kong, X., Liu, X., Xu, X., Liu, B.-L., & Ma, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1622526 · Cited by 2
Self-citationSind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Iftikhar, P., Khatri, C. P., Nanduri, S. R. D., Ramzan, M. A., & Sakalabaktula, K. S. K. (2025) · Cureus · doi:10.7759/cureus.87188 · Cited by 3
“Moreover, gastrointestinal adverse effects, including nausea, constipation, and diarrhea, remain a common issue with these drugs [5].”
Yang, F., Zhou, L., Zhang, J., Wang, Q., Cai, Q., Wang, J., Wu, C., Li, X., Zhang, J., Zheng, Y., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003156 · Cited by 1
Pieber, T. R., Švehlíková, E., Urva, S., Haupt, A., Zhou, C., Coşkun, T., Höller, V., Fluhr, G., Karanikas, C. A., Miličević, Z., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1627947 · Cited by 4
Akwe, J. A., Fongeh, K., Jung, S. A., Hall, M. A. K., Patidar, V., & Shin, Y. M. (2025) · Cureus · doi:10.7759/cureus.91677 · Cited by 4
Metabolic syndrome in the elderly
Dudinskaya, Е. N., Matchekhina, L. V., & Onuchina, Y. S. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6542 · Cited by 4
Jia, W., Jiang, F., Xu, Y., Li, Y., Bao, Y., & WANG, Q. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70112 · Cited by 1
ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine
Russo, S. L. M. L., Proto, L., Neto, M. G., Angelini, G., Pezzica, S., Carli, F., Previti, E., Caristo, M. E., Bove, V., Chakaroun, R., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70167 · Cited by 3
Agha, A., Afandi, B. O., Alhammadi, W. I., Almaskari, H. J. M., Alshamsi, A., Saleem, M., & Kaabi, J. A. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100656 · Cited by 6
Kaneto, H., Kimura, T., Sanada, J., Iwamoto, Y., Shimoda, M., Nakanishi, S., & Kaku, K. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70165 · Cited by 1
Simultaneous Pancreas and Kidney Transplantation in Patients With Type 2 Diabetes Mellitus
Owen, R. V., Reynard, J., Thompson, E., Kourounis, G., Snowden, C. P., Maillo-Nieto, A., Shaw, J., Wilson, C. H., & White, S. A. (2025) · Transplant International · doi:10.3389/ti.2025.14772 · Cited by 2
“Obese patients with T2DM may bene fi t from the use of GLP-1/GIP analogues such as Semaglutide or Tirzepatide to lose weight [82, 83].”
Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus
Kurinami, N., Takada, M., Sugiyama, S., Yoshida, A., Hieshima, K., Suzuki, T., MIYAMOTO, F., Kajiwara, K., Jinnouchi, K., Ashida, K., et al. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2420 · Cited by 1
“In the A Study of Tirzepatide [LY3298176] in Participants with Type 2 Diabetes (SURPASS-2) trial, tirzepatide (5 to 15 mg) was superior to 1.0 mg of semaglutide in improving both HbA1c and body weight [5], in contrast to our results.”
InfluentialThe Cardiovascular and Macrovascular Benefits of Achieving Early Type 2 Diabetes Remission
Khachikyan, L., & Shubrook, J. H. (2025) · Diabetology · doi:10.3390/diabetology6100120 · Cited by 2
Box, M. W., Puga, T. B., Werthmann, N. J., Liu, Y., & Riehl, J. T. (2025) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-25-00312 · Cited by 1
Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes
Takemoto, M., Zhang, B., Hayashi, A., Yamagata, H., Yoshida, Y., Koshizaka, M., Onishi, S., Yamaga, M., Yoshida, T., Hashimoto, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-22337-z · Cited by 2
“Tirzepatide, a dual GIP and GLP-1R activator, has both glucose-lowering and weight-reducing effects 17 .”
The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy
Shestakova, M. V., & Bashlykova, R. O. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.10.203366 · Cited by 6
A narrative review on tirzepatide’s therapeutic potential in glycemic control and cardioprotection
Thiriveedi, M., Domingo, F. S., Yates, H., Baddam, S., Beblawy, R. E., Nimmana, B., & Patel, S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004055 · Cited by 7
Gryglewska-Wawrzak, K., Kapłon‐Cieślicka, A., Pawlak, A., Tomaszuk−Kazberuk, A., Rubiś, P., Niedziela, J. T., & Bielecka-Dabrowa, A. M. (2025) · Pharmaceuticals · doi:10.3390/ph18111726 · Cited by 4
“Specifically, the SURPASS-2 clinical program indicated that patients treated with tirzepatide exhibited better cardiovascular outcomes relative to those receiving only standard therapies to manage diabetes [74].”
Glucagon-like Peptide-1 Agonists and Exercise for Weight Reduction: A Review of Current Evidence
Owaidat, J. F., Zuaiter, S., Daseh, A. I., Nemrawi, F. A. A., Abu‐Jeyyab, M., & Al-Jafari, M. (2025) · JAP Academy Journal · doi:10.4103/japaj.japaj_5_24 · Cited by 1
Ross, M., Mulnick, S., Boye, K. S., Samuelson, A., Thieu, V. T., Longuet, C., Glass, J., & Hoog, M. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70290 · Cited by 1
Genetic drivers of histological progression in MASLD
Romeo, S. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.11.003 · Cited by 1
Redefining Cystic Fibrosis-Related Diabetes Management With Tirzepatide: A Case Report
Babu, Y. S., & Jayagopal, V. (2025) · Cureus · doi:10.7759/cureus.97448 · Cited by 2
“In the SURPASS-2 trial (NEJM, 2021), tirzepatide reduced HbA1c by 2.01-2.30% and body weight by 7.6-11.2 kg after 40 weeks, outperforming semaglutide 1 mg (-1.86% and -5.7 kg, respectively)[17].”
InfluentialPosition Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615i · Cited by 2
Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615 · Cited by 5
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2025rbgo200 · Cited by 2
Mood Disorders, Metabolic Bariatric Surgery, and Weight Loss Pharmacotherapy: a Research Update
Barbuti, M., Weiss, F., & Perugi, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00674-4 · Cited by 1
Duncan, J., Stevens, P. L., Bigby, E., Floyd, C., Malina, J., Nickens, J., Lambert, A., & Kantor, T. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100236 · Cited by 2
“Advances in pharmacotherapy, particularly the emergence of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists like tirzepatide have demonstrated substantial benefits in promoting weight loss and improving metabolic outcomes [2 – 6].”
Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes
Wilkinson, T. J., Goldney, J., Yates, T. E., Henson, J. J., Zaccardi, F., Khunti, K., Webb, D. R., Papamargaritis, D., & Davies, M. J. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf258 · Cited by 3
“…observational studies have shown that tirzepatide’s superiority over semaglutide extends beyond that of weight loss, with greater effects observed in reducing glycated haemoglobin (HbA1c) [19 ], all-cause mortality, adverse cardiovascular events and adverse kidney events in T2DM [20 , 21 ].”
Self-citationType 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
Liu, Y., Gang, X., Liu, X., Jiang, W., Yang, Y., & Wang, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1687601 · Cited by 3
“A study comparing tirzepatide and semaglutide in patients with T2DM showed that greater effectiveness in reducing HbA1c and achieving weight loss was observed with tirzepatide treatment (both P 0.001) (49).”
InfluentialTirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison
Shil, K. K., Hira, A. D., Bakchi, S., Paul, S., Hossain, M., & Ghosh, D. K. (2025) · Cureus · doi:10.7759/cureus.98858 · Cited by 6
“For example, a study of tirzepatide versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes (SURPASS-2) reported 10-12 kg weight loss with tirzepatide 10-15 mg versus ~6 kg with semaglutide 1 mg [18].”
Liu, T., Hsu, C.-H., Wu, J., Huang, P., Chang, C., & Lai, C.-C. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.11.016 · Cited by 5
Wu, R., Xing, B., Zhou, Z., Yu, L., & Wang, H. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08680-z · Cited by 1
Neves, J. S., Leite, A. R., Vale, C., Marques, P., Vasques‐Nóvoa, F., Leite-Moreira, A. F., & Ferreira, J. P. (2025) · Diabetologia · doi:10.1007/s00125-025-06637-7 · Cited by 5
Prescribing Patterns and Adverse Effects of Semaglutide: A Real-World Comparative Evaluation
Whorton, A., Osman, S., Johal, J., Baig, S., Jones, A., & Jalal, Z. (2025) · Healthcare · doi:10.3390/healthcare14010035 · Cited by 1
“However, this finding also coincides with the 2023 UK approval of tirzepatide, a dual GLP-1/GIP agonist, which demonstrated superior glycaemic and weight outcomes compared to semaglutide in the SURPASS programme [30].”
Jalan, A., Murzinski, E. S., Jansen, P. J., Miller, R. D., Embry, M. C., Scherer, R. B., Moomaw, J. F., Williams, K. M., Fisher, C. A., James, J., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202520060 · Cited by 2
Hiraide, T., Suzuki, Y., Yamamoto, S., Yagihashi, S., & Sano, M. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-01161-1 · Cited by 2
Cuan, K., Lu, T., Goettemoeller, T., Xie, X., Rikin, S., Baron, S. W., Crandall, J. P., & Carruthers, D. J. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.12.016 · Cited by 1
Understanding metabolic bariatric surgery stigma through the lived experiences of Dutch women
Garcia, F. K., Mulder, B. C., Wagemakers, A., Hazebroek, E. J., & Verkooijen, K. T. (2026) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2026.100699 · Cited by 3
Agrawal, M., Kumar, A., Singh, A. K., Singh, H., Kumar, P., & Kumar, P. (2026) · Current Hypertension Reviews · doi:10.2174/0115734021389208251113105243 · Cited by 3
Sraboni, A., & Farhana, K. M. (2026) · Journal of Biochemistry Pharmacology and Public Health · doi:10.64907/xkmf.v4.i1.jbpph.1 · Cited by 1
Fu, L., Fan, J., Zhong, J., Xie, X., Yang, S., & Yue, X. (2026) · Clinical Medicine Frontiers · doi:10.57237/j.cmf.2026.01.001 · Cited by 1
“Additionally, a total of three studies [12, 14, 17] have re-ported on the comparison between Tir-zepatide and duraglutide/semaglutide/insulin.”
Shah, P. P., & Bhattacharya, R. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101418 · Cited by 2
“1 , Panel B) [15,16] The take-home message for patients is that these drugs are 98-99 % identical to our natural hormones; the modifications simply make them work better as medicines.”
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Management of Diabetes Mellitus: A Review
Singh, V., Yadav, V., Awasthi, V., Yadav, R., Shukla, S., Gupta, D., & Shukla, A. K. (2025) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.4.6.15 · Cited by 1
A New Era in the Medical Management of Obesity
Porterfield, F., Fatima, A., Boaventura, B. C. B., Madhar, A., Srivastava, G., & Stanford, F. C. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-125437 · Cited by 3
A Case of Euglycemic Diabetic Ketoacidosis With Tirzepatide Use and Severe Calorie Restriction
Raptis, D., Theodoropoulos, P., Shah, M. K., Bloomgarden, N. A., & Kishore, P. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf324 · Cited by 3
Ishigaki, Y., Yamada, M., Shingaki, T., Oura, T., & Shimomura, I. (2026) · Obesity · doi:10.1002/oby.70131 · Cited by 2
Chandra, K. P., GUPTA, M., Awasthi, R., Pande, A. R., Gupta, N., Kumar, D., Agarwal, V., Gupta, T., AWASTHI, S., & Lachhwani, H. (2026) · Cureus · doi:10.7759/cureus.102866 · Cited by 2
“In the SURPASS-2 trial, tirzepatide demonstrated superior reductions in HbA1c and body weight compared to semaglutide 1 mg, achieving mean HbA1c reductions ranging from 2.01% to 2.46% across different doses (5 mg, 10 mg, and 15 mg) compared to 1.86% with semaglutide [13].”
InfluentialChen, Q., Chen, T., Lin, W., & Chen, X. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s585436 · Cited by 3
Prado, B. S., Mazzotti, D. R., Franci, A., Baracioli, L., Barbado, K. R., Saretta, R., Filho, R. K., & Drager, L. F. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoaf071 · Cited by 1
Boye, K. S., Cutts, K. N., Coyne, K. S., & Matza, L. S. (2026) · Advances in Therapy · doi:10.1007/s12325-025-03448-5 · Cited by 1
“The two most commonly used non-insulin injectable medications in this sample were tirzepatide and injectable semaglutide, which have both demonstrated benefits for blood glucose control and weight reduction [36].”
Zhang, F., Chen, W., Wang, H., Wu, D., Chen, Z., Cheng, R., Hu, J., Xie, L., Qiu, Y., Zhou, Z., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.02.006 · Cited by 3
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
Obesity in children and adolescents
Berman, C., Kohn, B., & Wilson, D. P. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.07.004 · Cited by 7
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
Belančić, A., Antza, C., Poutachidis, A., Palaska, S., Gkrinia, E. M. M., Faour, A. K., Şener, Y. Z., Şener, S., & Sultana, R. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70492 · Cited by 1
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.